Although HbA 1c is widely used for diagnosis and management of diabetes in clinical practice and research studies, management of the incidental detection of hemoglobin variants (e.g., hemoglobin S [HbS], HbC) by common HbA 1c methods, such as ion exchange high-performance liquid chromatography (HPLC), is not well established. Many clinical laboratories do not report the presence of hemoglobin variants, whereas others report them only if they interfere with HbA 1c measurement (1) . As routine HbA 1c testing may incidentally yield information regarding hemoglobin variants that can affect clinical care, planning for appropriate management is warranted.
The Vitamin D and Type 2 Diabetes (D2d) Study is a multicenter, randomized, placebo-controlled trial testing whether vitamin D supplementation reduces diabetes incidence in people at high risk (2) As hemoglobin variant detection is an intrinsic part of HbA 1c testing by HPLC (i.e., an "anticipatable" incidental finding, in the parlance of the Presidential Commission for the Study of Bioethical Issues), planning for the handling of this information was indicated. A key consideration favoring notification is that people may use knowledge of their hemoglobin variant carrier status in reproductive decision making to modify risk for offspring of serious conditions such as sickle cell disease (4) . Knowledge of carrier status may also potentially provide direct health benefit to carriers. For example, among African Americans, HbS trait is associated with an increased risk of chronic kidney disease. Furthermore, some hemoglobin variants may alter red blood cell half-life, which could affect the accuracy and interpretation of HbA 1c levels.
Given these considerations, along with the relatively low risk associated with disclosing the finding (e.g., subsequent recognition of misattributed paternity), we determined that notifying participants was appropriate. Consequently, D2d investigators developed a plan for handling the incidental detection of hemoglobin variants. Single-page informational handouts on the two most common variants (HbS and HbC) briefly introduce the topic, suggest that the participant may want to share the finding with his or her primary care provider, and note that meeting with a genetic counselor could be considered if the participant is thinking of having children. A D2d staff member notifies the participant at the next study visit, and the relevant informational handout is shared and discussed. Notification, while occasionally eliciting surprise, has not yielded negative feedback from staff or affected participants.
Many clinical laboratories use HPLC assays for HbA 1c and elect not to report hemoglobin variants (1) . Likely underlying this practice is the generally asymptomatic nature of carrier status. Additionally, many clinical providers are unaware that hemoglobin variants may be detected incidentally during HbA 1c testing (5) and may not be prepared to discuss such findings. Our approach to notification may be generalizable to clinical settings. Although we generated study-specific materials for distribution (available at http:// www.d2dstudy.org/hemoglobin-variant), the National Institute of Diabetes and Digestive and Kidney Diseases has developed online resources on this topic for providers and affected individuals. As the detection of hemoglobin variants when measuring HbA 1c by HPLC is foreseeable and is common in racially diverse populations, this occurrence should be anticipated and requires a plan for appropriate management in clinical medicine and research. Vickery of the D2d Coordinating Center at Tufts Medical Center for her help in the preparation of the manuscript. The investigators gratefully acknowledge the commitment and dedication of the D2d participants. A.S., L.S.P., N.R., and A.G.P. contributed to design of the work, to the interpretation of the findings, and to the critical revision of the manuscript. M.R.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Data are n or n (%). *Other hemoglobin variants included elevated hemoglobin F (n 5 1) and probable HbE trait (n 5 2).
